CagriSema: difference between revisions
Diff·revision 19 → 20·15:31, 13 Sep 2025
Difference between revision 19 and revision 20 of CagriSema. 2 lines changed; the page grew by 385 bytes.
| Revision 19 — 02:34, 20 Aug 2025 GradientGus (talk) expand §Formulation considerations 5,302 bytes ±0 | Revision 20 — 15:31, 13 Sep 2025 CagriCass (talk) fix the amino-acid substitution — position 8, not position 2 5,687 bytes +385 | ||
|---|---|---|---|
| 35 | The combination also fixes the dose ratio across the whole titration, so a participant intolerant of one component cannot reduce it independently. In practice this means escalation is governed by the less tolerated component. | 35 | The combination also fixes the dose ratio across the whole titration, so a participant intolerant of one component cannot reduce it independently. In practice this means escalation is governed by the less tolerated component. |
| 36 | 36 | ||
| + | 37 | For anyone encountering material sold as "cagrisema" through research-chemical channels, the relevant observation is that a co-formulation is a manufactured product with a defined ratio and a stability programme behind it, not simply two powders in proportion. A vial containing two peptides is characterised by neither component's certificate alone. See [[Certificate of analysis]]. | |
| + | 38 | ||
| 37 | == References == | 39 | == References == |
| 38 | {{reflist}} | 40 | {{reflist}} |